Skip to main content
KYORIN Pharmaceutical Co., Ltd. logo

KYORIN Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 4569 ISIN · JP3247090008 T Manufacturing
Open in API
Filings indexed 58 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country JP Japan
Listing T 4569

About KYORIN Pharmaceutical Co., Ltd.

https://www.kyorin-pharm.co.jp/en/

KYORIN Pharmaceutical Co., Ltd. is a research-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription (ethical) and generic drugs. The company's commercial and R&D activities are focused on key therapeutic areas, including respiratory medicine, urology, otolaryngology (ENT), and inflammatory bowel disease (IBD). Through its subsidiaries, such as KYORIN Rimedio Co., Ltd., it also handles the manufacturing and distribution of generic medicines. The company is committed to providing a stable supply of high-quality pharmaceutical products to medical institutions and patients.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification regarding the accuracy of a previously filed semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. H1 68
2025-11-13 Japanese
半期報告書－第68期(2025/04/01－2025/09/30)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Semi-Annual Report' (半期報告書) filed by Kyorin Pharmaceutical Co., Ltd. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and audit review information for the interim period ending September 30, 2025. As it is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial data, it is classified as an Interim/Quarterly Report. H1 2025
2025-11-13 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act following the resolution of the '第67回定時株主総会' (67th Annual General Meeting). Section 2 details the resolutions passed, specifically the election of six directors, and provides the voting results (votes for, against, abstentions, and approval percentages). This content—reporting the results of a shareholder vote following an AGM—directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to an AGM, the core purpose is reporting the *results* of the vote, not providing the meeting materials (AGM-R) or proxy information (PSI).
2025-06-26 Japanese
内部統制報告書－第67期(2024/04/01－2025/03/31)
Governance Information Classification · 1% confidence The document is titled "内部統制報告書" (Internal Control Report) and explicitly references the legal basis as "金融商品取引法第24条の４の４第１項" (Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act). It details the scope, criteria, and procedures for evaluating internal controls over financial reporting as of the fiscal year-end (March 31, 2025), concluding that the internal controls are effective. This structure and content precisely match the requirements for an Internal Control Report, which is often filed alongside the Annual Report (10-K) but is a distinct regulatory filing in Japan. Given the specific Japanese regulatory context and the document's focus on internal control assessment, the closest equivalent category among the provided definitions is 'Audit Report / Information' (AR), as it covers internal/regulatory stress tests and applied accounting principles/reports, although 'Internal Control Report' is a specific type of assurance report. However, since there is no specific code for 'Internal Control Report' (J-SOX), and it is a formal report on internal controls, AR is the most appropriate fit among the choices, as it covers standalone audit/assurance reports. The document is the report itself, not an announcement of the report.
2025-06-19 Japanese
確認書
Audit Report / Information Classification · 1% confidence The document is extremely short (613 characters) and contains a table structure typical of a cover page for a Japanese regulatory filing. Key Japanese terms are present: "【提出書類】確認書" (Filing Document: Confirmation Document), "【根拠条文】金融商品取引法第24条の４の２第１項" (Basis Article: Financial Instruments and Exchange Act Article 24-4-2, Paragraph 1), and it explicitly mentions confirming the appropriateness of the "有価証券報告書" (Annual Securities Report) for the fiscal year ending March 31, 2025. This structure strongly suggests a certification or confirmation document related to the Annual Securities Report (which is equivalent to a 10-K in the US context, but the document itself is the confirmation, not the full report). Since the document is a confirmation/attestation regarding the accuracy of the Annual Securities Report, and it is not the full report itself, it falls under the general category of regulatory filings that attest to compliance or provide specific regulatory confirmations. Given the options, this is a specific regulatory confirmation document. While it relates to the 10-K content, the document type is a confirmation ('確認書'). In the context of the provided definitions, this is a specific regulatory filing that doesn't fit perfectly into 10-K (the full report) or ER (earnings release). It is a formal regulatory submission. The closest fit among the provided codes for a specific regulatory confirmation/attestation document that is not a full report or earnings release is often categorized under general regulatory filings (RNS) or, if it were a US equivalent, a certification. Given the nature of confirming the 'Annual Securities Report' (有価証券報告書), and its brevity, it is a specific regulatory filing. Since there is no specific code for 'Annual Report Certification', and it is not the full report (10-K), nor an earnings release (ER), nor a proxy statement (DEF 14A), the most appropriate fallback for a specific, non-standard regulatory confirmation document is RNS (Regulatory Filings). However, if we interpret 'AR' (Audit Report / Information) broadly to include formal attestations related to annual financial statements, it could be considered. Given the explicit reference to confirming the *Annual Securities Report* (which is the Japanese equivalent of the 10-K), and the document being a formal confirmation required by law, it is a highly specific regulatory document. Since the document is a confirmation of the *Annual Securities Report* (which is the 10-K equivalent), and it is not the full report, it is best classified as a specific regulatory filing. RNS is the best general regulatory fallback. FY 2025
2025-06-19 Japanese
有価証券報告書－第67期(2024/04/01－2025/03/31)
Annual Report Classification · 1% confidence The document header explicitly identifies itself as an '有価証券報告書' (Annual Securities Report) under the Financial Instruments and Exchange Act, Article 24, Paragraph 1. It covers a full fiscal year (第67期, 2024-04-01 to 2025-03-31) for Kyorin Pharmaceutical Co., Ltd. In the Japanese regulatory context, the '有価証券報告書' is the equivalent of the US 10-K annual report, containing comprehensive financial statements and business disclosures. FY 2025
2025-06-19 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.